Trial · NCT04956276
Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
NCT04956276, Phase 2, Withdrawn, Alexion Pharmaceuticals, Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia. Trials, record NCT04956276. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04956276
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
- NCT number
- NCT04956276
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Conditions
- Warm Autoimmune Hemolytic Anemia
- Interventions
- ALXN1830, Placebo
- First posted
- 2021-07-09
- Last updated
- 2022-02-11
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion Of Participants Achieving A ≥ 2 Grams/Deciliter (g/dL) Increase In Hemoglobin (Hgb) From Baseline To The End Of Primary Treatment | Baseline through Week 12 | Participants will have to achieve this increase without requiring any increase in the dose of an existing WAIHA medication after Day 1 (baseline) and without packed red blood cells (pRBC) transfusions after Day 14. |
| Secondary | Total Number Of Units Of pRBCs Transfused | Baseline through Week 12 | |
| Secondary | Number Of Hgb Measurements ≥ 2 g/dL From Baseline To The End Of Primary Treatment | Baseline, Week 12 | |
| Secondary | Time To Hgb Increase By ≥ 2 g/dL From Baseline | Baseline through Week 12 | |
| Secondary | Proportion Of Participants Who Require New WAIHA Rescue Medication Or Any Increase In The Dose Of An Existing WAIHA Medication Or pRBC Transfusions For The Treatment Of Anemia | Day 15 through Week 12 | |
| Secondary | Proportion Of Participants Achieving A ≥ 2 g/dL Increase In Hgb From Baseline Through Week 4 | Baseline through Week 4 | Participants need to achieve this increase without requiring any increase in the dose of an existing WAIHA medication after Day 1 and without pRBC transfusions after Day 14. |
| Secondary | Change From Baseline To The End Of Primary Treatment In Serum Lactate Dehydrogenase (LDH) Levels | Baseline, Week 12 | |
| Secondary | Change From Baseline To The End Of Primary Treatment In Absolute Reticulocyte Count | Baseline, Week 12 | |
| Secondary | Change From Baseline To The End Of Primary Treatment In Serum Indirect Bilirubin | Baseline, Week 12 | |
| Secondary | Change From Baseline To The End Of Primary Treatment In Serum Haptoglobin | Baseline, Week 12 |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04956276
GET https://conductscience.org/api/trials/v1/NCT04956276/registered?page=2